Mounjaro 7.5mg To Wegovy: Which Treatment Suits You?
Mounjaro 7.5mg To Wegovy: Understanding The Key Treatment Differences
When considering the transition from Mounjaro 7.5mg to Wegovy, understanding the fundamental differences between these prescription-only medicines is crucial. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist, whilst Wegovy contains semaglutide, targeting GLP-1 receptors exclusively. This mechanistic difference means each treatment works slightly differently on your body's appetite and satiety signals. The 7.5mg Mounjaro dose represents a mid-range maintenance level, whilst Wegovy's maximum maintenance dose is 2.4mg, reflecting the different potencies and mechanisms of each active ingredient.
Both treatments require careful dose escalation and cannot be switched directly without proper medical supervision. Your prescriber will assess whether transitioning from Mounjaro 7.5mg to Wegovy requires starting at Wegovy's initial 0.25mg dose and following the standard escalation schedule. This approach ensures your body adapts properly to the different mechanism of action. EverydayMeds' clinical team, operating under GPhC registration #9012878, provides guidance on both treatment pathways to help determine the most suitable option for your circumstances.
Wegovy Vs Mounjaro: Complete Pricing Comparison For Every Dose
Understanding the cost implications when comparing Mounjaro 7.5mg to Wegovy helps inform your treatment decision. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access these prices. Our Getting Started bundles provide convenience for dose progression, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, ensuring seamless treatment continuity.
Mounjaro pricing follows a different structure reflecting its distinct dosing schedule, with the 7.5mg dose representing a significant treatment investment. When evaluating Mounjaro 7.5mg to Wegovy costs, consider the total treatment journey rather than individual pen prices. Wegovy's maintenance dose of 2.4mg at £209.99 provides ongoing monthly treatment cost clarity. Our bundle options like the Ultimate Stability Trio (three 2.4mg pens for £649.99) support long-term maintenance therapy with Reliable Supply continuity and reduced ordering frequency.
Clinical Evidence: Mounjaro 7.5mg To Wegovy Treatment Outcomes
Clinical trials demonstrate both treatments' effectiveness when used alongside a reduced-calorie diet and increased physical activity. In the STEP trials, patients taking Wegovy achieved an average weight reduction of approximately 15% at 68 weeks (Wilding et al., NEJM, 2021). The STEP 2 trial showed average weight reductions of 9.6% in patients with type 2 diabetes, whilst STEP 5 demonstrated sustained weight management of 15.2% at two years.
Mounjaro's SURMOUNT trials revealed different outcome patterns reflecting the dual GIP and GLP-1 mechanism. When considering Mounjaro 7.5mg to Wegovy, remember that trial populations, endpoints, and methodologies differed significantly, making direct comparison inappropriate. Both treatments showed cardiovascular benefits in their respective studies, with Wegovy's SELECT trial demonstrating a 20% reduction in major cardiovascular events.
How Wegovy Works: GLP-1 Mechanism For Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormones to support weight management. When administered once weekly via the FlexTouch pen, semaglutide binds to GLP-1 receptors in your brain's appetite centres, potentially reducing hunger signals and promoting satiety after smaller meals. This mechanism may help decrease food cravings and support portion control when combined with lifestyle modifications. The treatment works gradually, requiring dose escalation from 0.25mg through to the 2.4mg maintenance dose over 16 weeks. Unlike some weight management approaches, Wegovy targets the physiological pathways that regulate appetite and food intake, supporting sustainable changes in eating patterns.
Ordering Process: From Assessment To Next-Day Delivery
EverydayMeds streamlines access to both Wegovy and Mounjaro through our efficient online process designed for busy lifestyles. Complete our comprehensive 3-minute clinical assessment covering your medical history, current medications, and weight management goals to ensure treatment suitability. Our qualified prescribers review every application, with standard reviews completed within 3 working days and express reviews available within 24 hours for urgent requirements. Once approved, your prescription-only medicine ships via next-day delivery using our temperature-controlled cold-chain system to maintain medication integrity. Our pharmacy team, registered with the GPhC under number #9012878, ensures every order meets the highest safety and quality standards. You'll receive tracking information and storage instructions with every delivery, plus ongoing support from our clinical team throughout your treatment journey.
Storage And Practical Considerations: Wegovy Vs Mounjaro
Storage requirements present a key practical difference when comparing Mounjaro 7.5mg to Wegovy options. Wegovy pens remain stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This storage advantage makes Wegovy particularly suitable for frequent travellers or those with limited refrigeration access. Both treatments require initial refrigerated storage at 2-8°C until first use, with the FlexTouch pen design ensuring accurate dosing throughout the temperature-stable period. The once-weekly injection schedule for both treatments supports adherence, though the longer room temperature stability of Wegovy provides additional flexibility for maintaining your dosing schedule during travel or unexpected circumstances.
Mounjaro 7.5mg To Wegovy: Transitioning Between Dual And Single Receptor Agonists
Switching from Mounjaro 7.5mg to Wegovy involves transitioning from a dual GIP and GLP-1 receptor agonist to a pure GLP-1 agonist, requiring careful medical supervision. Your prescriber will typically recommend starting Wegovy at the 0.25mg dose regardless of your current Mounjaro level, ensuring your body adapts to the different mechanism safely. This restart approach prevents potential adverse effects and allows proper dose optimisation for the semaglutide-based treatment.
The transition period requires monitoring for effectiveness and tolerability differences between the two mechanisms. Some patients notice changes in appetite suppression patterns or gastrointestinal effects when switching between tirzepatide and semaglutide. EverydayMeds provides ongoing clinical support throughout this transition, ensuring you receive appropriate guidance and monitoring to optimise your weight management outcomes with either treatment option.
Complete Your Wegovy Or Mounjaro Assessment Today
Both Wegovy and Mounjaro represent evidence-based approaches to weight management, each with distinct advantages depending on your individual circumstances and preferences. Start your clinical assessment today using discount codes FIRST40 for new customers or DOSE25 for returning customers to access our competitive pricing from £79.99. Our experienced clinical team will help determine whether Wegovy's GLP-1 mechanism or Mounjaro's dual receptor approach better aligns with your treatment goals. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your assessment and discover which prescription-only medicine offers the most suitable pathway for your weight management journey. Remember that both treatments work most effectively alongside a reduced-calorie diet and increased physical activity, supported by our comprehensive patient guidance materials.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
